Cord blood banking can positively change lives! Share with those you care about! youtu.be/tfbK1orr1H0 Call: (866) 389-4659 or visit stemcyte.com to review plans and enroll with StemCyte, the Pioneer in Regenerative Therapeutics.

StemCyte's Sweetheart Special! 1. Exceptional pricing for Cord Blood and Tissue Preservation 2. Complimentary StemCyte CARE ($699 value) 3. StemVita Skincare Trio ($260 value) Call (866) 389-4659 or visit StemCyte.com to take advantage of this SUPER sweet deal!

Take a few moments and learn the truth about cord blood stem cells and how they can protect your growing family! Cord blood stem cells can treat 80+ health conditions and diseases. Call us at (866) 389-4659 or visit us online to learn more! ow.ly/K1DV50DsrF9

StemCyte Inc. receives reaccreditation by AABB. Medical Director Lawrence Petz, MD, confirms zero nonconformances and an acknowledgement by the agency of the company's commitment to quality, whether banking publicly or privately. prn.to/2VimhPK

StemCyte Announces Breakthrough Allogeneic Cell Therapy Technology in cover page article featured in the July 28 issue of Advanced Materials (Impact Factor: 27.4). prn.to/3Cd9Eqr

"With acute stroke being the second and third leading cause of death and disability, respectively, worldwide, this outcome is as outstanding as it was unexpected.” Jonas Wang, StemCyte Chairman & President prn.to/3g4o3es

In the past 20 years, StemCyte has provided more than 2,200 cord blood units for transplantation to 1 in 20 patients worldwide who receive umbilical cord blood transplants. prn.to/3D1dALy

Since 2013, 83% of transplant units through the CA-UCBCP have been provided by StemCyte prn.to/3l7gGpq

With FDA approval of the our Phase II IND, StemCyte aims to treat Post-COVID Syndrome by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair for long-term effect. prn.to/3wCpnhk

Cord blood is a cell therapy biological drug that StemCyte is investigating to repair fatigue and brain fog commonly seen in Post-COVID symptoms. The first Post-COVID Syndrome Phase II clinical trial has begun recruiting patients. prn.to/3OHsm1Z

StemCyte signs a cooperation agreement with a cutting-edge US immune cell therapy company to supply drug preparation raw materials for allogeneic modified cell therapy prn.to/3qA6z2m

We’re so grateful to connect the Women’s Care of Beverly Hills Medical Group! A wonderful chance to get together with their team and celebrate women’s health. Big thanks to Longshot Coffee for the adorable StemCyte lattes that made the day even sweeter ☕💜 #CordBlood

We had an incredible few days connecting with clinicians, researchers, and partners at #AABB 2025. Learn more about REGENECYTE™ and download our company profile: is.gd/VOGXvt Cell starting materials: [email protected] #StemCyte #AABB #CordBlood #CellTherapy